Astrazeneca Plc Stock Fair Value Calculation – ASTRAZENECA PLC Reports 359.7% Increase in Fourth Quarter Revenue for FY2022.
March 13, 2023
Earnings Overview
ASTRAZENECA ($LSE:AZN): However, their reported net income for the quarter decreased 6.7% year over year to USD 11207.0 million.
Share Price
On Thursday, ASTRAZENECA PLC reported an impressive fourth-quarter revenue for FY2022 of 359.7%, sending the stock soaring to a 4.1% increase from its prior closing price of 107.5. ASTRAZENECA PLC opened at £110.4 and closed at £111.9, furthering the company’s reach as one of the leading pharmaceuticals in the world. This rise in revenue can be attributed to the strong performance of key products such as Crestor and Tagrisso, both of which reported double-digit growth and contributed to the financial success of the company.
In addition, the company’s focus on research and development has allowed them to expand their portfolio to include new products and treatments that have been highly successful in the market. Overall, ASTRAZENECA PLC continues to demonstrate their industry-leading abilities by consistently delivering record-breaking results each quarter. Investors are eagerly awaiting the company’s next quarterly report, expecting similar levels of success to be achieved and a further increase in the share price. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Astrazeneca Plc. More…
| Total Revenues | Net Income | Net Margin |
| 44.35k | 3.29k | 7.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Astrazeneca Plc. More…
| Operations | Investing | Financing |
| 9.81k | -2.96k | -6.82k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Astrazeneca Plc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 96.48k | 59.42k | 23.9 |
Key Ratios Snapshot
Some of the financial key ratios for Astrazeneca Plc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 22.1% | 7.8% | 8.7% |
| FCF Margin | ROE | ROA |
| 16.3% | 6.7% | 2.5% |
Analysis – Astrazeneca Plc Stock Fair Value Calculation
At GoodWhale, we specialize in analyzing the financials of leading organizations around the world. Recently, we have been closely examining ASTRAZENECA PLC, one of the world’s largest pharmaceutical companies. Our analysis led us to calculate the fair value of ASTRAZENECA PLC’s shares at £114.8. Surprisingly, the current market price of ASTRAZENECA PLC’s stock stands at £111.9 per share, which is lower than our fair value calculation by 2.5%. This means that ASTRAZENECA PLC shares are currently undervalued and present a good opportunity for investors. More…
Peers
AstraZeneca PLC is a pharmaceutical company that specializes in the development, manufacture, and marketing of prescription drugs. The company has a diversified product portfolio, which includes medications for cardiovascular, gastrointestinal, and respiratory diseases, as well as cancer. AstraZeneca PLC competes with Sanofi SA, Merck & Co Inc, and Pfizer Inc in the global pharmaceutical market.
– Sanofi SA ($OTCPK:SNYNF)
As of 2022, Sanofi SA has a market cap of 100.1B and a Return on Equity of 7.56%. The company is a French multinational pharmaceutical company headquartered in Paris, France, and is one of the world’s largest pharmaceutical companies. Sanofi is a diversified company, focused on human health. It covers seven areas: diabetes solutions, rare diseases, multiple sclerosis, oncology, immunology, vaccines and consumer healthcare.
– Merck & Co Inc ($NYSE:MRK)
Merck & Co Inc is a pharmaceutical company with a market cap of 236.25B as of 2022. The company has a return on equity of 28.84%. The company produces a variety of drugs and vaccines for human and animal health.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is a research-based pharmaceutical company with a market cap of 241.95B as of 2022. The company has a return on equity of 24.63%. Pfizer’s main focus is on the discovery, development, and commercialization of innovative therapeutics to treat patients with serious diseases. The company has a portfolio of products in various therapeutic areas, including cardiovascular, inflammation, immunology, oncology, pain, and rare diseases.
Summary
Investors in ASTRAZENECA PLC saw a positive return on Dec. 31, 2022, as the company reported a 359.7% increase in total revenue and a 6.7% decrease in net income compared to the previous year. Despite the decline in net income, the stock price moved up on the news, indicating that investors are looking past the short-term decline in profit and anticipating future growth. Analysists remain optimistic about the company’s prospects for the coming year, given its impressive revenue growth. Long-term investors should consider seeking additional research and advice before investing in ASTRAZENECA PLC.
